Höbaus Clemens, Herz Carsten Thilo, Pesau Gerfried, Wrba Thomas, Koppensteiner Renate, Schernthaner Gerit-Holger
1 Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
2 IT4Science, IT Systems & Communications, Medical University of Vienna, Vienna, Austria.
Angiology. 2018 May;69(5):424-430. doi: 10.1177/0003319717728226. Epub 2017 Aug 29.
Fatty acid-binding protein 4 (FABP4) is a possible biomarker of atherosclerosis. We evaluated FABP4 levels, for the first time, in patients with peripheral artery disease (PAD) and the possible association between baseline FABP4 levels and cardiovascular events over time. Patients (n = 327; mean age 69 ± 10 years) with stable PAD were enrolled in this study. Serum FABP4 was measured by bead-based multiplex assay. Cardiovascular events were analyzed by FABP4 tertiles using Kaplan-Meier and Cox regression analyses after 5 years. Serum FABP4 levels showed a significant association with the classical 3-point major adverse cardiovascular event (MACE) end point (including death, nonlethal myocardial infarction, or nonfatal stroke) in patients with PAD ( P = .038). A standard deviation increase of FABP4 resulted in a hazard ratio (HR) of 1.33 (95% confidence interval [95% CI]: 1.03-1.71) for MACE. This association increased (HR: 1.47, 95% CI: 1.03-1.71) after multivariable adjustment ( P = .020). Additionally, in multivariable linear regression analysis, FABP4 was linked to estimated glomerular filtration rate ( P < .001), gender ( P = .005), fasting triglycerides ( P = .048), and body mass index ( P < .001). Circulating FABP4 may be a useful additional biomarker to evaluate patients with stable PAD at risk of major cardiovascular complications.
脂肪酸结合蛋白4（FABP4）是动脉粥样硬化的一种潜在生物标志物。我们首次评估了外周动脉疾病（PAD）患者的FABP4水平，以及基线FABP4水平与随时间发生的心血管事件之间的可能关联。本研究纳入了327例稳定型PAD患者（平均年龄69±10岁）。采用基于微珠的多重检测法测定血清FABP4。5年后，使用Kaplan-Meier法和Cox回归分析，按FABP4三分位数分析心血管事件。血清FABP4水平与PAD患者的经典3点主要不良心血管事件（MACE）终点（包括死亡、非致死性心肌梗死或非致死性卒中）显著相关（P = 0.038）。FABP4每增加一个标准差，MACE的风险比（HR）为1.33（95%置信区间[95%CI]：1.03 - 1.71）。多变量调整后，这种关联增强（HR：1.47，95%CI：1.03 - 1.71）（P = 0.020）。此外，在多变量线性回归分析中，FABP4与估计肾小球滤过率（P < 0.001）、性别（P = 0.005）、空腹甘油三酯（P = 0.048）和体重指数（P < 0.001）相关。循环FABP4可能是评估有主要心血管并发症风险的稳定型PAD患者的一种有用的额外生物标志物。
